Cited by 487Barrier Structure and Function StudiesAdvanced Drug Delivery SystemsNerve injury and regeneration

The DOI matches its Crossref record; 310 of the 310 references it cites were found in a registry or an index.

Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations

Thorne, Robert G., Frey, William H.·2001·Clinical Pharmacokinetics

DOI 10.2165/00003088-200140120-00003

Open this paper in CoChat — free account

Abstract

Neurotrophic factors are proteins with considerable potential in the treatment of central nervous system (CNS) diseases and traumatic injuries. However, a significant challenge to their clinical use is the difficulty associated with delivering these proteins to the CNS. Neurotrophic factors are hydrophilic, typically basic, monomeric or dimeric proteins, mostly in the size range of 5 to 30 kDa. Neurotrophic factors potently support the development, growth and survival of neurons, eliciting biological effects at concentrations in the nanomolar to femtomolar range. They are not orally bioavailable and the blood-brain and blood-cerebrospinal fluid barriers severely limit their ability to enter into and act on sites in the CNS following parenteral systemic routes of administration. Most neurotrophic factors have short in vivo half-lives and poor pharmacokinetic profiles. Their access to the CNS is restricted by rapid enzymatic inactivation, multiple clearance processes, potential immunogenicity and sequestration by binding proteins and other components of the blood and peripheral tissues. The development of targeted drug delivery strategies for neurotrophic factors will probably determine their clinical effectiveness for CNS conditions. Achieving significant CNS target site concentrations while limiting systemic exposure and distribution to peripheral sites of action will lessen unwanted pleiotropic effects and toxicity. Local introduction of neurotrophic factors into the CNS intraparenchymally by direct injection/infusion or by implantation of delivery vectors such as polymer matrices or genetically modified cells yields the highest degree of targeting, but is limited by diffusion restrictions and invasiveness. Delivery of neurotrophic factors into the cerebrospinal fluid (CSF) following intracerebroventricular or intrathecal administration is less invasive and allows access to a much wider area of the CNS through CSF circulation pathways. However, diffusional and cellular barriers to penetration into surrounding CNS tissue and significant clearance of CSF into the venous and lymphatic circulation are also limiting. Unconventional delivery strategies such as intranasal administration may offer some degree of CNS targeting with minimal invasiveness. This review presents a summary of the neurotrophic factors and their indications for CNS disorders, their physicochemical characteristics and the different approaches that have been attempted or suggested for their delivery to the CNS. Future directions for further research such as the potential for CNS disease treatment utilising combinations of neurotrophic factors, displacement strategies, small molecule mimetics, chimaeric molecules and gene therapy are also discussed.

Integrity signals

Registry

Crossref · 10.2165/00003088-200140120-00003

Cites

310 of 310 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Items 201–310 of 310

Insulin‐like Growth Factor Receptors: Implications for Nervous System Function
LeRoith, D., Werner, H., Faria, T. N., Kato, H., Adamo, M. L., & Roberts, C. T. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb26202.x · Cited by 70
Transport of Insulin‐Related Peptides and Glucose across the Blood‐Brain Barriera
Pardridge, W. M. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb26211.x · Cited by 70
A Phase I Study of Recombinant Human Ciliary Neurotrophic Factor (rHCNTF) in Patients with Amyotrophic Lateral Sclerosis
&NA; (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199512000-00004 · Cited by 70
Blood-Brain Barrier Transport of 125I-Labeled Basic Fibroblast Growth Factor
Deguchi, Y., Naito, T., Yuge, T., Furukawa, A., Yamada, S., Pardridge, W. M., & Kimura, R. (2000) · Pharmaceutical Research · doi:10.1023/a:1007570509232 · Cited by 68
The relevance to humans of animal models for inhalation studies of cancer in the nose and upper airways.
DeSesso, J. M. (1993) · PubMed · Cited by 67
Total synthesis of insulin-like growth factor I (somatomedin C).
Li, C. H., Yamashiro, D., Gospodarowicz, D., et al. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.8.2216 · Cited by 65
Stabilization of nerve growth factor in controlled release polymers and in tissue
Krewson, C. E., Dause, R. B., Mak, M., & Saltzman, W. M. (1997) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856296x00183 · Cited by 64
Distribution of [125I]nerve growth factor in the rat brain following a single intraventricular injection: Correlation with the topographical distribution of trk a messenger RNA-expressing cells
Lapchak, P. A., Araujo, D. M., Carswell, S., & Hefti, F. F. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90265-h · Cited by 64
Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging
Date, I., Yoshimoto, Y., Imaoka, T., et al. (1993) · Brain Research · doi:10.1016/0006-8993(93)90312-b · Cited by 64
Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain
Mahoney, M. J., & Saltzman, W. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4536 · Cited by 64
Bone Morphogenetic Proteins and Bone Morphogenetic Protein Gene Therapy in Neurological Surgery: A Review
Helm, G. A., Alden, T. D., Sheehan, J. P., et al. (2000) · Neurosurgery · doi:10.1097/00006123-200005000-00038 · Cited by 63
Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications
Zou, L., Huang, L., Hayes, R. L., Black, C., Qiu, Y. H., Perez-Polo, J. R., Le, W., Clifton, G. L., & Yang, K. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300936 · Cited by 59
Mammalian GFRα-4, a Divergent Member of the GFRα Family of Coreceptors for Glial Cell Line-derived Neurotrophic Factor Family Ligands, Is a Receptor for the Neurotrophic Factor Persephin
Masure, S., Cik, M., Hoefnagel, E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003867200 · Cited by 59
Controlled Release of Proteins to Tissue Transplants for the Treatment of Neurodegenerative Disorders
Mahoney, M. J., & Saltzman, W. M. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js9601602 · Cited by 59
Peptide and Protein Drug Analysis
Reid, R. E. (1999) · CRC Press eBooks · doi:10.1201/9781420001334 · Cited by 58
Axonal regeneration of sensory nerves is delayed by continuous intrathecal infusion of nerve growth factor
Gold, B. G. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00416-2 · Cited by 58
Neuroprotective Utility and Neurotrophic Action of Neurturin in Postnatal Motor Neurons: Comparison with GDNF and Persephin
Bilak, M. M., Shifrin, D. A., Corse, A. M., Bilak, S. R., & Kuncl, R. W. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0756 · Cited by 57
AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells
Middlemiss, P. J., Glasky, A. J., Rathbone, M. P., et al. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12029-4 · Cited by 57
Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington’s disease
Pérez‐Navarro, E., Åkerud, P., Marco, S., Canals, J. M., Tolosa, E., Arenas, E., & Alberch, J. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00074-9 · Cited by 57
The movement of IGF-I into the brain parenchyma after hypoxic-ischaemic injury
Guan, J., Skinner, S. J. M., Beilharz, E. J., Hua, K. M., Hodgkinson, S., Gluckman, P. D., & Williams, C. E. (1996) · Neuroreport · doi:10.1097/00001756-199601310-00061 · Cited by 57
Interaction of nerve growth factor with murine α‐macroglobulin
Koo, P. H., & Stach, R. W. (1989) · Journal of Neuroscience Research · doi:10.1002/jnr.490220304 · Cited by 57
Localized Delivery of Proteins in the Brain: Can Transport Be Customized?
Haller, M. F., & Saltzman, W. M. (1998) · Pharmaceutical Research · doi:10.1023/a:1011911912174 · Cited by 55
Intravenous Fibroblast Growth Factor Penetrates the Blood-Brain Barrier and Protects Hippocampal Neurons Against Ischemia-Reperfusion Injury
Cuevas, P., Carceller, F., B.Sc., I. M.-W., & B.Sc., G. G.-G. (1998) · Surgical Neurology · doi:10.1016/s0090-3019(97)00193-6 · Cited by 55
Insulinlike growth factor binding proteins
Spagnoli, A., & Rosenfeld, R. G. (1997) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-199702000-00001 · Cited by 54
Nerve Growth Factor Treatment in Dementia
Eriksdotter, M. (2000) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200000001-00006 · Cited by 53
Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity
Gozes, I., Davidson, A., Gozes, Y., Mascolo, R., Barth, R. N., Warren, D., Hauser, J. M., & Brenneman, D. E. (1997) · Developmental Brain Research · doi:10.1016/s0165-3806(96)00215-5 · Cited by 53
Identical or Overlapping Sequences in the Primary Structure of Human α2-Macroglobulin Are Responsible for the Binding of Nerve Growth Factor-β, Platelet-derived Growth Factor-BB, and Transforming Growth Factor-β
Gonias, S. L., Carmichael, A., Mettenburg, J., Roadcap, D. W., Irvin, W. P., & Webb, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5826 · Cited by 53
Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor
Clairmont, K. B., & Czech, M. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98868-x · Cited by 52
The blood-brain barrier and multiple sclerosis.
Moor, A. C. E., de Vries, H. D., de Boer, A. G., & Breimer, D. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90297-6 · Cited by 52
Evidence for pore-like opening of the blood-brain barrier following forebrain ischemia in rats
Preston, E., & Foster, D. O. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00323-5 · Cited by 52
Increased CSF levels of nerve growth factor in patients with Alzheimer’s disease
Hock, C., Heese, K., Müller-Spahn, F., Huber, P., Riesen, W., Nitsch, R. M., & Otten, U. (2000) · Neurology · doi:10.1212/wnl.54.10.2009 · Cited by 52
Tracer diffusion of proteins in DNA solutions
Wattenbarger, M. R., Bloomfield, V. A., Bu, Z., & Russo, P. S. (1992) · Macromolecules · doi:10.1021/ma00046a024 · Cited by 51
Localization of mRNA for leukemia inhibitory factor receptor in the adult rat brain
Hisashi, Y., Masabumi, M., & Masamichi, S. (1996) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00097-5 · Cited by 50
Putrescine‐Modified Nerve Growth Factor: Bioactivity, Plasma Pharmacokinetics, Blood‐Brain/Nerve Barrier Permeability, and Nervous System Biodistribution
Poduslo, J. F., Curran, G. L., & Gill, J. S. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041651.x · Cited by 50
Neurotrophic Factors: What Are They and What Are They Doing?
Hefti, F. F., Denton, T. L., Knüsel, B., & Lapchak, P. A. (1993) · Elsevier eBooks · doi:10.1016/b978-0-08-057132-4.50006-x · Cited by 49
The Influence of the Blood Pressure in Urographic Examination
Wickbom, I. G. (1950) · Acta Radiologica · doi:10.3109/00016925009176556 · Cited by 49
Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects
Riekkinen, P. J., Legros, J., Sennef, C., Jolkkonen, J., Smitz, S., & Soininen, H. S. (1987) · Peptides · doi:10.1016/0196-9781(87)90101-x · Cited by 49
Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats
Hao, J., Ebendal, T., Xu, X., Wiesenfeld‐Hallin, Z., & Eriksdotter, M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01107-1 · Cited by 49
Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: Distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons
Mufson, E. J., Kroin, J. S., Liu, Y.-T., Sobreviela, T., Penn, R. D., Miller, J., & Kordower, J. H. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00431-9 · Cited by 47
The Pharmacokinetics of Subcutaneously Administered Recombinant Human Ciliary Neurotrophic Factor (rHCNTF) in Patients with Amyotrophic Lateral Sclerosis
&NA; (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199512000-00003 · Cited by 47
Behavioral effects of neurohypophyseal peptides in healthy volunteers: 10 years of research
Fehm‐Wolfsdorf, G., & Born, J. (1991) · Peptides · doi:10.1016/0196-9781(91)90226-f · Cited by 46
Nomenclature of GPI-Linked Receptors for the GDNF Ligand Family
GFRα Nomenclature Committee (1997) · Neuron · doi:10.1016/s0896-6273(00)80365-7 · Cited by 46
LIF (AM424), a promising growth factor for the treatment of ALS.
Kurek, J., Radford, A., Crump, D., Bower, J., Feeney, S. J., Austin, L., & Byrne, E. (1998) · Journal of Neurological Sciences · doi:10.1016/s0022-510x(98)00208-1 · Cited by 45
Orally active NGF synthesis stimulators: potential therapeutic agents in alzheimer's disease
Yamada, K., Nitta, A., Hasegawa, T., Fuji, K., Hiramatsu, M., Kameyama, T., Furukawa, Y., Hayashi, K., & Nabeshima, T. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)86054-8 · Cited by 45
Pharmacological induction of physiologically active nerve growth factor in rat peripheral nervous system.
Kaechi, K., Furukawa, Y., Ikegami, R., et al. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10271-1 · Cited by 45
Tracer Diffusion of Proteins in DNA Solutions. 2. Green Fluorescent Protein in Crowded DNA Solutions
Busch, N. A., Kim, T., & Bloomfield, V. A. (2000) · Macromolecules · doi:10.1021/ma0005724 · Cited by 44
X-linked adrenoleukodystrophy enigma: How does the ALD peroxisomal transporter mutation affect CNS glia?
Aubourg, P. R., & Dubois-Dalcq, M. E. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000115)29:2 · Cited by 42
Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
Venero, J. L., Hefti, F. F., & Knüsel, B. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08712-7 · Cited by 42
Merkel complexes of human digital skin: Three-dimensional imaging with confocal laser microscopy and double immunofluorescence
Guinard, D., Usson, Y., Guillermet, C., & Saxod, R. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980817)398:1 · Cited by 41
Interaction of Nerve Growth Factor with the Mouse-Brain Neurotubule Protein(s)
Calissano, P., & Cozzari, C. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.5.2131 · Cited by 41
A Soluble brain molecule related to epidermal growth factor receptor is a mitogen inhibitor for astrocytes
Nieto‐Sampedro, M., & Broderick, J. T. (1989) · Journal of Neuroscience Research · doi:10.1002/jnr.490220105 · Cited by 40
Neurotrophic Factors in the Treatment of Peripheral Neuropathy
Apfel, S. C., & Kessler, J. A. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514863.ch8 · Cited by 38
Human epidermal growth factor—on molecular forms present in urine and blood
Nexø, E., Jørgensen, P. E., & Hansen, M. R. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90025-p · Cited by 38
Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats
Kim, D. C., Sugiyama, Y., Fuwa, T., et al. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90033-6 · Cited by 37
TGFα and the Blood–Brain Barrier: Accumulation in Cerebral Vasculature
Pan, W., Vallance, K., & Kastin, A. J. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7215 · Cited by 36
Chemistry, structure, and function of insulin-like growth factors and their receptors: a review
Perdue, J. F. (1984) · Canadian Journal of Biochemistry and Cell Biology · doi:10.1139/o84-158 · Cited by 36
Gene Expression along the Cerebral-Spinal Axis after Regional Gene Delivery
Meuli‐Simmen, C., Liu, Y., Yeo, T. T. S., Liggitt, D., Tu, G., Yang, T., Meuli, M., Knauer, S., Heath, T. D., Longo, F. M., et al. (1999) · Human Gene Therapy · doi:10.1089/10430349950016735 · Cited by 36
Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli
Negro, A., Corona, G., Bigon, E., Martini, I., Grandi, C., Skaper, S. D., & Callegaro, L. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490290216 · Cited by 36
The pharmacokinetics of free insulin-like growth factor-I in healthy subjects
Frystyk, J., Hussain, M. A., Skjærbæk, C., et al. (1999) · Growth Hormone & IGF Research · doi:10.1054/ghir.1999.0100 · Cited by 35
Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration
Sullivan, A. M., Opacka‐Juffry, J., Pohl, J., et al. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01275-x · Cited by 35
Solution Structure and Internal Motion of a Bioactive Peptide Derived from Nerve Growth Factor
Beglova, N., LeSauteur, L., Ekiel, I. H., Saragovi, H. U., & Gehring, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.23652 · Cited by 34
The brain and the lymphatic system (I).
Földi, M. (1996) · PubMed · Cited by 33
Biochemistry and Molecular Biology of Fibroblast Growth Factors
Thomas, K. A. (1993) · Elsevier eBooks · doi:10.1016/b978-0-08-057132-4.50013-7 · Cited by 33
Distribution of Radioiodinated Recombinant Human Nerve Growth Factor in Primate Brain Following Intracerebroventricular Infusion
Emmett, C. J., Stewart, G. R., Johnson, R. M., et al. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0125 · Cited by 33
Role of p53 in DNA strand break-induced apoptosis in organotypic slice culture from the mouse cerebellum
Inamura, N., Araki, T., Enokido, Y., Nishio, C., Aizawa, S., & Hatanaka, H. (2000) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(20000515)60:4 · Cited by 33
The first attempt at radioisotopic evaluation of the integrity of the nose-brain barrier
Okuyama, S. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00149-5 · Cited by 32
Intracerebral transportation and cellular localisation of insulin-like growth factor-1 following central administration to rats with hypoxic–ischemic brain injury
Guan, J., Beilharz, E. J., Skinner, S. J. M., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02030-2 · Cited by 32
Cholecystokinin-8 protects central cholinergic neurons against fimbria–fornix lesion through the up-regulation of nerve growth factor synthesis
Tirassa, P., Aloe, L., Stenfors, C., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6473 · Cited by 32
The blood-brain barrier to horseradish peroxidase at the onset of bicuculline-induced seizures in hypothalamus, pallidum, hippocampus, and other selected regions of the rabbit
Nitsch, C., Goping, G., Laursen, H. B., et al. (1986) · Acta Neuropathologica · doi:10.1007/bf00687032 · Cited by 31
Evidence for Central Nervous Effects of Corticotropin-Releasing Hormone on Gastric Acid Secretion in Humans
Kern, W., Schiefer, B., Schwarzenburg, J., et al. (2008) · Neuroendocrinology · doi:10.1159/000127187 · Cited by 31
Local Reduction of Organ Size in Transgenic Mice Expressing a Soluble Insulin-Like Growth Factor II/Mannose-6-Phosphate Receptor
Zaina, S., Newton, R. V. S., Paul, M. R., et al. (1998) · Endocrinology · doi:10.1210/endo.139.9.6200 · Cited by 30
NGF and Alzheimer's: Hopes and Fears
Marx, J. L. (1990) · Science · doi:10.1126/science.2405484 · Cited by 29
Soluble insulin-like growth factor-II/mannose 6-P receptor inhibits deoxyribonucleic acid synthesis in cultured rat hepatocytes.
Scott, C. D., Ballesteros, M., Madrid, J., et al. (1996) · Endocrinology · doi:10.1210/endo.137.3.8603597 · Cited by 25
Insulin-Like Growth Factors in the Brain
LeRoith, D., Roberts, C. T., Werner, H., Bondy, C. A., Raizada, M. K., & Adamo, M. L. (1993) · Elsevier eBooks · doi:10.1016/b978-0-08-057132-4.50017-4 · Cited by 24
Comparative Binding of Neurotrophins (NT-3, CNTF and NGF) and Various Cytokines to α2-Macroglobulin
Liebl, D. J., & Koo, P. H. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1760 · Cited by 24
Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency
Skjærbæk, C. B. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00876.x · Cited by 24
Concentration dependence of protein diffusion
O’Leary, T. J. (1987) · Biophysical Journal · doi:10.1016/s0006-3495(87)83199-5 · Cited by 24
Recommendations for Nomenclature of the Insulin-Like Growth Factor Binding Protein Superfamily
Baxter, R. C., Binoux, M., Clemmons, D. R., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5083 · Cited by 21
Serum free insulin-like growth factor-I is dose-dependently decreased by methylprednisolone and related to body weight changes in rats
Skjærbæk, C. B., Frystyk, J., Grøfte, T., et al. (1999) · Growth Hormone & IGF Research · doi:10.1054/ghir.1999.0090 · Cited by 20
Proteins I: Composition and Structure
Schultz, R. M., Liebman, M., & Angstadt, C. N. (2002) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471254959.dev003 · Cited by 20
Peptide and Protein Drugs
McMartin, C. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78680-8_13 · Cited by 19
Combating Parkinson's Disease--Step Three
Olson, L. (2000) · Science · doi:10.1126/science.290.5492.721 · Cited by 19
Interaction of [125I]? nerve growth factor with acidic proteins
Rusenko, K. W., & Stach, R. W. (1981) · Neurochemical Research · doi:10.1007/bf00964044 · Cited by 19
A fibroblast growth factor binding protein in human cerebral spinal fluid
Hanneken, A. M., Frautschy, S. A., Galasko, D. R., et al. (1995) · Neuroreport · doi:10.1097/00001756-199504190-00015 · Cited by 18
Enhanced delivery of [125I]glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification
Jiao, S., Miller, P. J., & Lapchak, P. A. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13265-1 · Cited by 18
Physicochemical Characterization of Recombinant Human Nerve Growth Factor Produced in Insect Cells with a Baculovirus Vector
Barnett, J. W., Chow, J. M., Nguyen, B. T., et al. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08256.x · Cited by 18
Clinical Applications of Neurotrophic Factors
Apfel, S. C. (1997) · Cited by 17
Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats
Frystyk, J., Grønbæk, H., Skjærbæk, C., et al. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.5.e840 · Cited by 17
Effect of Recombinant Human Growth Hormone and Insulin‐Like Growth Factor‐1 Administration on IGF‐1 and IGF‐Binding Protein‐3 Levels in Brain Injury
Rockich, K. T., Hatton, J., Kryscio, R. J., et al. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.18.1432.30891 · Cited by 16
Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum
Nitta, A., Ogihara, Y., Onishi, J., et al. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00133-1 · Cited by 15
CNTF II, I presume?
Lesser, S. S., & Lo, D. C. (2000) · Nature Neuroscience · doi:10.1038/78738 · Cited by 14
Developmental changes in nerve growth factor level in rat serum
Murase, K., Takeuchi, R., Iwata, E., Furukawa, Y., Furukawa, S., & Hayashi, K. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490330211 · Cited by 14
Pharmacokinetic considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein
Rowland, M., & McLachlan, A. J. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353518 · Cited by 14
A Compartmental Model for Simulation of IGF-I Kinetics and Metabolism
Sönksen, P. H., Jones, R. H., & Boroujerdi, M. A. (1994) · Methods of Information in Medicine · doi:10.1055/s-0038-1635049 · Cited by 14
The Effect of Nasal Patency on the Clearance of Radiolabeled Saline in Healthy Volunteers
Washington, N., McGlashan, J. A., Jackson, S. J., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007590501540 · Cited by 13
Lay-offs follow suspension of clinical trials of protein
Verrall, M. (1994) · Nature · doi:10.1038/370006a0 · Cited by 11
Nervous Excitement over Neurotrophic Factors
Walsh, G. (1995) · Nature Biotechnology · doi:10.1038/nbt1195-1167 · Cited by 11
Reversible sedimentation and masking of nerve growth factor (NGF) antigen by high molecular weight fractions from rat brain
Hoener, M. C., & Varon, S. S. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00745-2 · Cited by 11
Stability and Interactions of Recombinant Human Nerve Growth Factor in Different Biological Matrices: In Vitro and In Vivo Studies
Nguyen, C. B., Szönyi, É., Sadick, M. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15105-7 · Cited by 11
Epidermal Growth Factor: Structure, Expression, and Functions in the Central Nervous System
Morrison, R. S. (1993) · Elsevier eBooks · doi:10.1016/b978-0-08-057132-4.50015-0 · Cited by 10
Previously reported nerve growth factor levels are underestimated due to an incomplete release from receptors and interaction with standard curve media
Fawcett, J. R., Chen, X., Rahman, Y., et al. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01817-x · Cited by 8
Gene therapy to the rescue in Parkinson's disease
Mandir, A. S., Dawson, V. L., & Dawson, T. M. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01638-2 · Cited by 5
Separation and microanalysis of growth factors by Phast system gel electrophoresis and by DNA synthesis in cell culture
Kuo, K.-W., Yeh, H.-W., Chu, D. Z. J., et al. (1991) · Journal of Chromatography A · doi:10.1016/s0021-9673(01)95797-8 · Cited by 5
Epi-Arachnoidal Drug Deposit
Ochs, G., Giess, R., Bendszus, M., et al. (1999) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(99)00067-6 · Cited by 4
Kidney as an important metabolic organ for recombinant human insulin-like growth factor-I.
Tanaka, Y., Kitao, K., Hata, T., et al. (1997) · PubMed · Cited by 4
Assessing Commercial Potential of Central Nervous System Delivery Approaches
Swen, J. S., Flanagan, T. R., & Wiggans, T. G. (1994) · Methods in neurosciences · doi:10.1016/b978-0-12-185291-7.50034-5 · Cited by 4
The Effect of Route of Administration and Distribution on Drug Action
Benet, L. Z., & Oie, S. (2002) · Drugs and the pharmaceutical sciences · doi:10.1201/9780824744694.ch5 · Cited by 3
Strategies for Administering Neurotrophic Factors to the Central Nervous System
Hottinger, A. F., & Aebischer, P. (1999) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-59920-0_10 · Cited by 1
Propentofylline Prevents Neuronal Dysfunction Induced by Infusion of Anti-Nerve Growth Factor Antibody into the rat Septum.
Nitta, Atsumi, Ogihara, et al. (1997) · 岐阜藥科大學紀要 = The annual proceedings of Gifu College of Pharmacy · Cited by 1
Untitled work
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3

Research works printed but not linked: 15

Walsh, 1995, Biol Technol, 13, 1167
Desai, 1999, Mor Mortal Wkly Rep CDC Surveill Summ, 48, 7
Foldi, 1996, Lymphology, 29, 1
Kuo, 1991, J Chromatogr B Biomed Sci Appl, 543, 463
Tanaka, 1997, Res Commun Mol Pathol Pharmacol, 96, 267
Frystyk, 1995, Am J Physiol, 269, E840
Fung, 1998, Cancer Res, 58, 672
Penn, 1997, Neurosurgery, 40, 94
Apfel, 1996, Ciba Found Symp, 196, 98
de Vries, 1996, J Pharmacol Exp Ther, 277, 1418
Venero, 1996, Mol Pharmacol, 49, 303
DeSesso, 1993, Qual Assur, 2, 213
Bojsen-Moller, 1971, J Anat, 110, 25
Kaechi, 1993, J Pharmacol Exp Ther, 264, 321
Tuszynski, 1996, Gene Ther, 3, 305

Sorted by citations

Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Self-citation
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Self-citation
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
The blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380

See all 487

Authors: Thorne, R. G., & Frey, W. H.
Affiliations: Regions Hospital (US)
ORCID: Thorne, Robert G.
Frey, William H.
Venue: Clinical Pharmacokinetics
Publisher: Springer Science and Business Media LLC
Published: 2001
Volume: 40
Issue: 12
Pages: 907-946
ISSN: 0312-5963 (ISSN-L)
DOI: 10.2165/00003088-200140120-00003
OpenAlex: W1973304468
Cited by: 487
References: 310
Citations by year: 2026: 10 · 2025: 15 · 2024: 19 · 2023: 20 · 2022: 21 · 2021: 24 · 2020: 31 · 2019: 17 · 2018: 24 · 2017: 17 · 2016: 26 · 2015: 26 · 2014: 26 · 2013: 28 · 2012: 20
FWCI: 1.14
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacokinetics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords: neurotrophic factors, brain drug delivery, blood-brain barrier, blood-CSF barrier, intrathecal administration, intracerebroventricular administration, intranasal drug delivery, intraparenchymal injection, gene therapy, small molecule mimetics, central nervous system disorders, traumatic brain injury, pharmacokinetics, immunogenicity
MeSH terms: Animals, Central Nervous System Diseases, Drug Combinations, Humans, Nerve Growth Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks